{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:40:21Z","timestamp":1788993621124,"version":"build-2803163510"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2026.103089","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:22:07Z","timestamp":1768004527000},"page":"103089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer"],"prefix":"10.1016","volume":"143","author":[{"given":"Clara Salva","family":"de Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Saoudi","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez-Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iosune","family":"Baraibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Salv\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"\u00c9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-3832","authenticated-orcid":false,"given":"Enrique","family":"Sanz-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103089_b0005","unstructured":"World Health Organization. Global Cancer Today. Globocan 2022. Available online: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/pie?mode=cancer&group_populations=1 (accessed on 29 August 2025)."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103089_b0015","article-title":"Microsatellite Instability and Metastatic Colorectal Cancer - a Clinical Perspective. Front","volume":"12","author":"Buchler","year":"2022","journal-title":"Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103089_b0020","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103089_b0025","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ijc.32744","article-title":"Association of PD-L1 expression status with the efficacy of PD-1\/PD-L1 inhibitors and overall survival in solid tumours: a systematic review and meta-analysis","volume":"147","author":"Liu","year":"2020","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103089_b0035","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103089_b0040","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/2159-8290.CD-21-0521","article-title":"PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon","volume":"12","author":"Rousseau","year":"2022","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103089_b0045","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.annonc.2022.08.084","article-title":"Leveraging big data of immune checkpoint blockade response identifies novel potential targets","volume":"33","author":"Bareche","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103089_b0050","doi-asserted-by":"crossref","unstructured":"Cindy Yang SY, Lien SC, Wang BX, et al. Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nat Commun. 2021;12(1):5137. Published 2021 Aug 26. doi:10.1038\/s41467-021-25432-7.","DOI":"10.1038\/s41467-021-25432-7"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103089_b0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10476","key":"10.1016\/j.ctrv.2026.103089_b0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103089_b0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0070","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103089_b0075","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant Immunotherapy in locally Advanced Mismatch Repair-Deficient Colon Cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103089_b0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1","article-title":"Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)","volume":"43","author":"Sinicrope","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103089_b0085","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103089_b0090","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 Blockade in Mismatch Repair-Deficient, locally Advanced Rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0095","first-page":"325","article-title":"A phase two, Single-arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II\/III dMMR\/MSI-H locally Advanced Rectal Cancer (AZUR-1)","volume":"24","author":"Cercek","year":"2025","journal-title":"Clin Colorectal Cancer"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103089_b0100","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative Management of Mismatch Repair-Deficient Tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103089_b0105","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2026.103089_b0110","doi-asserted-by":"crossref","unstructured":"Wang L, Geng H, Liu Y, et al. Hot and cold tumors: Immunological features and the therapeutic strategies. MedComm (2020). 2023;4(5):e343. Published 2023 Aug 26. doi:10.1002\/mco2.343.","DOI":"10.1002\/mco2.343"},{"key":"10.1016\/j.ctrv.2026.103089_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113495","article-title":"Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers","volume":"198","author":"Stemmer","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103089_b0130","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103089_b0135","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.22.02462","article-title":"Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline","volume":"41","author":"Vikas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0140","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jamaoncol.2018.4942","article-title":"Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer with Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status","volume":"5","author":"Cohen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103089_b0145","article-title":"Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer","volume":"6","author":"Salins","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103089_b0150","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.6279","article-title":"Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy","volume":"263","author":"Geurts","year":"2024","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2026.103089_b0155","doi-asserted-by":"crossref","unstructured":"Heregger R, Huemer F, Steiner M, Gonzalez-Martinez A, Greil R, Weiss L. Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer. Cancers (Basel). 2023;15(20):5090. Published 2023 Oct 21. doi:10.3390\/cancers15205090.","DOI":"10.3390\/cancers15205090"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103089_b0160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103089_b0165","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1158\/1078-0432.CCR-14-0567","article-title":"Genetic evolution of T-cell resistance in the course of melanoma progression","volume":"20","author":"Sucker","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10689-017-0013-y","article-title":"Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas","volume":"17","author":"Clendenning","year":"2018","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0175","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ijc.22691","article-title":"Beta2-microglobulin mutations in microsatellite unstable colorectal tumors","volume":"121","author":"Kloor","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2026.103089_b0180","article-title":"Majority of B2M-mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit from Immune Checkpoint Inhibitor Therapy and are Microsatellite Instability-High. JCO Precis","volume":"3","author":"Middha","year":"2019","journal-title":"Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103089_b0185","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/2326-6066.CIR-18-0683","article-title":"Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer","volume":"7","author":"Gurjao","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0190","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2026.103089_b0195","doi-asserted-by":"crossref","unstructured":"Mazet JM, Mahale JN, Tong O, et al. IFN\u03b3 signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity ofintra-tumoral stem-like T cells.Nat Commun. 2023;14(1):321. Published 2023 Jan 19. doi:10.1038\/s41467-023-35948-9.","DOI":"10.1038\/s41467-023-35948-9"},{"key":"10.1016\/j.ctrv.2026.103089_b0200","doi-asserted-by":"crossref","unstructured":"Albacker LA, Wu J, Smith P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS One. 2017;12(11):e0176181. Published 2017 Nov 9. doi:10.1371\/journal.pone.0176181.","DOI":"10.1371\/journal.pone.0176181"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0205","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0210","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000417","article-title":"B2M and JAK1\/2-mutated MSI-H Colorectal Carcinomas can Benefit from Anti-PD-1 Therapy","volume":"45","author":"Zhang","year":"2022","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103089_b0215","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","article-title":"Genetic Mechanisms of Immune Evasion in Colorectal Cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103089_b0220","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003414","article-title":"Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers","volume":"9","author":"Kim","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/0008-5472.CAN-22-1403","article-title":"Wnt Signaling in the Phenotype and Function of Tumor-Associated Macrophages","volume":"83","author":"Tigue","year":"2023","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103089_b0230","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","article-title":"MSIsensor: microsatellite instability detection using paired tumor-normal sequence data","volume":"30","author":"Niu","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ctrv.2026.103089_b0235","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6567998","article-title":"Identification of APC Mutation as a potential Predictor for Immunotherapy in Colorectal Cancer","volume":"2022","author":"Feng","year":"2022","journal-title":"J Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0240","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12876-023-02725-3","article-title":"APC mutation correlated with poor response of immunotherapy in colon cancer","volume":"23","author":"Li","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103089_b0245","doi-asserted-by":"crossref","first-page":"e6910","DOI":"10.1002\/cam4.6910","article-title":"Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: a retrospective study","volume":"13","author":"Liu","year":"2024","journal-title":"Cancer Med"},{"issue":"7693","key":"10.1016\/j.ctrv.2026.103089_b0250","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103089_b0255","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/1541-7786.MCR-20-0308","article-title":"A TGF\u03b2-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Colorectal Cancer","volume":"18","author":"Endo","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103089_b0260","doi-asserted-by":"crossref","unstructured":"Chen J, Ji C, Liu S, et al. Transforming growth factor-\u03b2 (TGF-\u03b2) signaling pathway-related genes in predicting the prognosis of colon cancer and guiding immunotherapy. Cancer Pathog Ther. 2023;2(4):299-313. Published 2023 Dec 12. doi:10.1016\/j.cpt.2023.12.002.","DOI":"10.1016\/j.cpt.2023.12.002"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103089_b0265","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4132\/jptm.2019.06.07","article-title":"Clinicopathological Characterization and Prognostic Implication of SMAD4 Expression in Colorectal Carcinoma","volume":"53","author":"Yoo","year":"2019","journal-title":"J Pathol Transl Med"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103089_b0270","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/his.14880","article-title":"Loss of function SMAD4 nonstop mutations in human cancer","volume":"82","author":"Bauer","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2026.103089_b0275","doi-asserted-by":"crossref","unstructured":"Fang T, Liang T, Wang Y, et al. Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21(1):297. Published 2021 Jul 23. doi:10.1186\/s12876-021-01864-9.","DOI":"10.1186\/s12876-021-01864-9"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0280","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tranon.2014.11.003","article-title":"A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer","volume":"8","author":"Voorneveld","year":"2015","journal-title":"Transl Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0285","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ijc.26473","article-title":"High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis","volume":"131","author":"Isaksson-Mett\u00e4vainio","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2026.103089_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ctrv.2026.103089_b0295","doi-asserted-by":"crossref","unstructured":"Chen W, Li L, Cheng S, Yu J. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials. Dis Markers. 2022;2022:2631852. Published 2022 Aug 26. doi:10.1155\/2022\/2631852.","DOI":"10.1155\/2022\/2631852"},{"key":"10.1016\/j.ctrv.2026.103089_b0300","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz453.001","article-title":"LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103089_b0305","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/1078-0432.CCR-20-4023","article-title":"Treatment Outcomes and Clinical Characteristics of patients with KRAS-G12C-mutant Non-Small Cell Lung Cancer","volume":"27","author":"Arbour","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0310","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 Axis Drives Immune suppression and Immune Therapy Resistance in Colorectal Cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103089_b0315","article-title":"Mutant KRAS triggers functional reprogramming of tumor-associated macrophages in colorectal cancer","volume":"6(1):144","author":"Liu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0320","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2326-6066.CIR-15-0241","article-title":"Mutant KRAS Conversion of conventional T Cells into Regulatory T Cells","volume":"4","author":"Zdanov","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2026.103089_b0325","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12(1):35","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103089_b0330","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0335","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/cr.2016.149","article-title":"Innate immune signaling and regulation in cancer immunotherapy","volume":"27","author":"Corrales","year":"2017","journal-title":"Cell Res"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103089_b0340","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s00262-022-03200-w","article-title":"Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR\/MSI colorectal cancer","volume":"71","author":"Kaneta","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0345","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21037\/atm-20-2430","article-title":"A STING-related prognostic score predicts high-risk patients of colorectal cancer and provides insights into immunotherapy","volume":"9","author":"Chen","year":"2021","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0350","first-page":"e164","article-title":"The Effects of Neoadjuvant Treatment on the Tumor Microenvironment in Rectal Cancer: Implications for Immune Activation and Therapy Response","volume":"19","author":"Chen","year":"2020","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0355","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/path.6415","article-title":"A Tc1- and Th1-T-lymphocyte-rich tumor microenvironment is a hallmark of MSI colorectal cancer","volume":"266","author":"Huang","year":"2025","journal-title":"J Pathol"},{"issue":"5795","key":"10.1016\/j.ctrv.2026.103089_b0360","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0365","doi-asserted-by":"crossref","first-page":"152","DOI":"10.23736\/S1824-4785.20.03249-5","article-title":"Immunoscore and its introduction in clinical practice","volume":"64","author":"Galon","year":"2020","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0370","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-23-2213","article-title":"Biomarkers of Pathologic complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer","volume":"30","author":"Li","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103089_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00055","article-title":"Intratumoral CD3+ and CD8+ T-Cell Densities in patients with DNA Mismatch Repair-Deficient Metastatic Colorectal Cancer Receiving Programmed Cell Death-1 Blockade","volume":"3","author":"Chakrabarti","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103089_b0380","article-title":"The Prognostic Implications of Tumor Infiltrating Lymphocytes in Colorectal Cancer","volume":"10(1):3360","author":"Idos","year":"2020","journal-title":"A Systematic Review and Meta-Analysis Sci Rep"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103089_b0385","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.2019-0611","article-title":"Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes","volume":"25","author":"Loupakis","year":"2020","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103089_b0390","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S2468-1253(24)00091-8","article-title":"Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis","volume":"9","author":"Wankhede","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0395","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2021.06.064","article-title":"Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts","volume":"161","author":"Bortolomeazzi","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0400","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ccell.2024.12.008","article-title":"A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer","volume":"43","author":"Acha-Sagredo","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103089_b0405","article-title":"CD74 as a prognostic and M1 macrophage infiltration marker in a comprehensive pan-cancer analysis","volume":"14(1):8125","author":"Li","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2026.103089_b0410","article-title":"Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability","volume":"21(1):161","author":"Wu","year":"2023","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103089_b0415","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0420","doi-asserted-by":"crossref","first-page":"497","DOI":"10.37349\/etat.2022.00097","article-title":"Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets","volume":"3","author":"Al-Mterin","year":"2022","journal-title":"Explor Target Antitumor Ther"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103089_b0425","first-page":"4268","article-title":"Immune Marker Spatial distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair-deficient","volume":"29","author":"Saberzadeh-Ardestani","year":"2023","journal-title":"Advanced Colorectal Carcinomas Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103089_b0430","doi-asserted-by":"crossref","unstructured":"Feng Y, Ma W, Zang Y, et al. Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients. Nat Commun. 2024;15(1):10259. Published 2024 Nov 26. doi:10.1038\/s41467-024-54710-3.","DOI":"10.1038\/s41467-024-54710-3"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103089_b0435","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103089_b0440","doi-asserted-by":"crossref","unstructured":"Gong Z, Huang X, Cao Q, Wu Y, Zhang Q. A CLRN3-Based CD8+ T-Related Gene Signature Predicts Prognosis and Immunotherapy Response in Colorectal Cancer. Biomolecules. 2024;14(8):891. Published 2024 Jul 24. doi:10.3390\/biom14080891.","DOI":"10.3390\/biom14080891"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103089_b0445","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.21037\/tcr-2025-1104","article-title":"Integrative single-cell and bulk transcriptomes analyses reveal T cell-related prognostic risk model and tumor immune microenvironment modulation in colorectal cancer","volume":"14","author":"Liu","year":"2025","journal-title":"Transl Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0450","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004001","article-title":"Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancers","volume":"10","author":"Fuc\u00e0","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103089_b0455","article-title":"Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice","volume":"8","author":"Alouani","year":"2023","journal-title":"An AGEO study ESMO Open"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0460","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/jso.24523","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review","volume":"115","author":"Haram","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2026.103089_b0465","article-title":"Inflammatory Markers Predict Survival in patients with Advanced Gastric and Colorectal Cancers Receiving Anti-PD-1 Therapy. Front Cell","volume":"9","author":"Fan","year":"2021","journal-title":"Dev Biol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103089_b0470","first-page":"230","article-title":"Clinical and Molecular Variables Associated with Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: a Retrospective Cohort Study","volume":"23","author":"Hulst","year":"2024","journal-title":"Clin Colorectal Cancer"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103089_b0475","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103089_b0480","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103089_b0485","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","article-title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","volume":"30","author":"Schrock","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103089_b0490","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","article-title":"Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project","volume":"32","author":"Vega","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103089_b0495","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor Mutational Burden as a Predictor of Immunotherapy Response: is more always Better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103089_b0500","doi-asserted-by":"crossref","unstructured":"Spaanderman IT, Peters FS, Jongejan A, Redeker EJW, Punt CJA, Bins AD. Framing the potential of public frameshift peptides as immunotherapy targets in colon cancer. PLoS One. 2021;16(6):e0251630. Published 2021 Jun 28. doi:10.1371\/journal.pone.0251630.","DOI":"10.1371\/journal.pone.0251630"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103089_b0505","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/0008-5472.CAN-14-3051","article-title":"Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: a Rationale for Personalized Immunotherapy","volume":"75","author":"Maby","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103089_b0510","doi-asserted-by":"crossref","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9. Published 2023 Jan 6. doi:10.1038\/s41392-022-01270-x.","DOI":"10.1038\/s41392-022-01270-x"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0515","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006464","article-title":"Predictive biomarkers for PD-1\/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data","volume":"11","author":"So","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103089_b0520","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx393.011","volume":"28","author":"Andr\u00e9","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0525","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.23.01524","article-title":"First-Line dual Immunotherapy, a Treatment Option in First-Line Metastatic Non-Small-Cell Lung Cancer: are we ready to use it?","volume":"42","author":"Uprety","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0530","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103089_b0535","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1158\/1078-0432.CCR-20-4009","article-title":"Association of Fusobacterium nucleatum with specific T-cell Subsets in the Colorectal Carcinoma Microenvironment","volume":"27","author":"Borowsky","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103089_b0540","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1158\/2326-6066.CIR-18-0174","article-title":"Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status","volume":"6","author":"Hamada","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0545","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00535-017-1382-6","article-title":"Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population","volume":"53","author":"Yamaoka","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ctrv.2026.103089_b0550","doi-asserted-by":"crossref","unstructured":"Wang Y, Wen Y, Wang J, et al. Clinicopathological differences of high Fusobacterium nucleatum levels in colorectal cancer: A review and meta-analysis. Front Microbiol. 2022;13:945463. Published 2022 Nov 4. doi:10.3389\/fmicb.2022.945463.","DOI":"10.3389\/fmicb.2022.945463"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0555","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chom.2013.07.012","article-title":"Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin\/\u03b2-catenin signaling via its FadA adhesin","volume":"14","author":"Rubinstein","year":"2013","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0560","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","article-title":"Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment","volume":"14","author":"Kostic","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ctrv.2026.103089_b0565","doi-asserted-by":"crossref","unstructured":"Zhang S, Yang Y, Weng W, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res. 2019;38(1):14. Published 2019 Jan 10. doi:10.1186\/s13046-018-0985-y.","DOI":"10.1186\/s13046-018-0985-y"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103089_b0570","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.annonc.2020.06.003","article-title":"Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer","volume":"31","author":"Serna","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0575","article-title":"Multi-omics of the gut microbial ecosystem in patients with microsatellite-instability-high gastrointestinal cancer resistant to immunotherapy","volume":"5","author":"Cheng","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103089_b0580","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-024-01622-6","article-title":"Role of the Microbiome and Diet for Response to Cancer Checkpoint Immunotherapy: a Narrative Review of Clinical Trials","volume":"27","author":"Gamrath","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"6575","key":"10.1016\/j.ctrv.2026.103089_b0585","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2026.103089_b0590","doi-asserted-by":"crossref","unstructured":"Somodi C, Dora D, Horv\u00e1th M, Szegvari G, Lohinai Z. Gut microbiome changes and cancer immunotherapy outcomes associated with dietary interventions: a systematic review of preclinical and clinical evidence. J Transl Med. 2025;23(1):756. Published 2025 Jul 8. doi:10.1186\/s12967-025-06586-0.","DOI":"10.1186\/s12967-025-06586-0"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103089_b0595","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/oncolo\/oyac162","article-title":"Antibiotic Exposure does not Impact Immune Checkpoint Blockade Response in MSI-H\/dMMR Metastatic Colorectal Cancer: a Single-Center Experience","volume":"27","author":"Serpas Higbie","year":"2022","journal-title":"Oncologist"},{"issue":"35","key":"10.1016\/j.ctrv.2026.103089_b0600","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2016.67.4283","article-title":"Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation","volume":"34","author":"Iyengar","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103089_b0605","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35799","article-title":"Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types","volume":"131","author":"Mastrolonardo","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103089_b0610","article-title":"Impact of body composition on pathological response to neoadjuvant immunotherapy in dMMR\/MSI-H colorectal cancer","volume":"16","author":"Zeng","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103089_b0615","article-title":"Single-cell transcriptome analysis reveals immunosuppressive landscape in overweight and obese colorectal cancer","volume":"22(1):134","author":"Xiao","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2026.103089_b0620","doi-asserted-by":"crossref","unstructured":"Kaiser M, Semeraro MD, Herrmann M, Absenger G, Gerger A, Renner W. Immune Aging and Immunotherapy in Cancer.Int J Mol Sci. 2021;22(13):7016. Published 2021 Jun 29. doi:10.3390\/ijms22137016.","DOI":"10.3390\/ijms22137016"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103089_b0625","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1634\/theoncologist.2015-0319","article-title":"Phase II Study of Olaparib (AZD-2281) after Standard Systemic Therapies for Disseminated Colorectal Cancer","volume":"21","author":"Leichman","year":"2016","journal-title":"Oncologist"},{"issue":"8011","key":"10.1016\/j.ctrv.2026.103089_b0630","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-024-07350-y","article-title":"Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers","volume":"629","author":"Ferretti","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103089_b0635","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007716","article-title":"Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer","volume":"12","author":"Martincuks","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2026.103089_b0640","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/j.annonc.2024.08.611","article-title":"542P long-term outcomes of neoadjuvant toripalimab with or without celecoxib in patients with dMMR\/MSI-H locally advanced colorectal cancer: 3-month treatment cohort of the randomized phase II PICC trial","volume":"35","author":"Hu","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103089_b0645","article-title":"SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells","volume":"29(1):80","author":"Anastasio","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"10.1016\/j.ctrv.2026.103089_b0650","doi-asserted-by":"crossref","unstructured":"Sullivan RJ et al. Trial START-001: A phase 1\/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment. JCO 2023 41:16_suppl, TPS2671-TPS2671 doi:10.1200\/JCO.2023.41.16_suppl.TPS2671.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2671"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:57:53Z","timestamp":1770479873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":130,"alternative-id":["S0305737226000034"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103089","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103089"}}